Literature DB >> 16772815

Treatment of catatonic stupor with combination of modified electroconvulsive treatment and olanzapine: a case report.

Qing Rong Tan1, Wen Wang, Huai Hai Wang, Rui Guo Zhang, Li Guo, Ya Hong Zhang.   

Abstract

This case report is about the combined use of modified electroconvulsive treatment and an atypical antipsychotic drug, olanzapine, in the treatment of a 20-year-old man with chronic and refractory catatonic stupor. This patient, with a preexisting diagnosis of autism, posturing, nonverbal communication, and contracture of lower extremities, displaying mutism, akinesia, and an extreme level of rigidity, waxy flexibility, and posturing, was diagnosed as with catatonic stupor. After hospitalization, the disease had progressed despite the treatment with an atypical antipsychotic drug, olanzapine. Modified electroconvulsive treatment together with olanzapine caused a dramatic clinical improvement. Follow-up outpatient treatment with olanzapine improved his social functions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16772815     DOI: 10.1097/01.WNF.0000220816.86478.84

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  3 in total

Review 1.  Catatonia in patients with autism: prevalence and management.

Authors:  Luigi Mazzone; Valentina Postorino; Giovanni Valeri; Stefano Vicari
Journal:  CNS Drugs       Date:  2014-03       Impact factor: 5.749

2.  A case report of schizoaffective disorder with ritualistic behaviors and catatonic stupor: successful treatment by risperidone and modified electroconvulsive therapy.

Authors:  Yuanhan Bai; Xi Yang; Zhiqiang Zeng; Haichen Yang
Journal:  BMC Psychiatry       Date:  2018-03-13       Impact factor: 3.630

3.  First known case of catatonia due to cyclosporine A-related neurotoxicity in a pediatric patient with steroid-resistant nephrotic syndrome.

Authors:  R David Heekin; Kalonda Bradshaw; Chadi A Calarge
Journal:  BMC Psychiatry       Date:  2019-04-24       Impact factor: 3.630

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.